344 related articles for article (PubMed ID: 30444176)
21. The effectiveness of Lee Silverman Voice Treatment therapy issued interactively through an iPad device: A non-inferiority study.
Griffin M; Bentley J; Shanks J; Wood C
J Telemed Telecare; 2018 Apr; 24(3):209-215. PubMed ID: 28147896
[TBL] [Abstract][Full Text] [Related]
22. Changes to articulation following LSVT(R) and traditional dysarthria therapy in non-progressive dysarthria.
Wenke RJ; Cornwell P; Theodoros DG
Int J Speech Lang Pathol; 2010 Jun; 12(3):203-20. PubMed ID: 20433339
[TBL] [Abstract][Full Text] [Related]
23. [Speech therapy of dysarthria in Parkinson's disease].
Cabrejo L; Auzou P; Ozsancak C; Hannequin D
Presse Med; 2003 Nov; 32(37 Pt 1):1745-51. PubMed ID: 14663391
[TBL] [Abstract][Full Text] [Related]
24. The impact of Lee Silverman Voice Treatment (LSVT LOUD®) on voice, communication, and participation: Findings from a prospective, longitudinal study.
Bryans LA; Palmer AD; Anderson S; Schindler J; Graville DJ
J Commun Disord; 2021; 89():106031. PubMed ID: 33259945
[TBL] [Abstract][Full Text] [Related]
25. Non-invasive stimulation of the auditory feedback area for improved articulation in Parkinson's disease.
Brabenec L; Klobusiakova P; Barton M; Mekyska J; Galaz Z; Zvoncak V; Kiska T; Mucha J; Smekal Z; Kostalova M; Rektorova I
Parkinsonism Relat Disord; 2019 Apr; 61():187-192. PubMed ID: 30337204
[TBL] [Abstract][Full Text] [Related]
26. Speech treatment in Parkinson's disease: Randomized controlled trial (RCT).
Ramig L; Halpern A; Spielman J; Fox C; Freeman K
Mov Disord; 2018 Nov; 33(11):1777-1791. PubMed ID: 30264896
[TBL] [Abstract][Full Text] [Related]
27. Long-term effects of Lee Silverman Voice Treatment on daily voice use in Parkinson's disease as measured with a portable voice accumulator.
Körner Gustafsson J; Södersten M; Ternström S; Schalling E
Logoped Phoniatr Vocol; 2019 Oct; 44(3):124-133. PubMed ID: 29447488
[TBL] [Abstract][Full Text] [Related]
28. Effects of an intensive voice treatment on articulatory function and speech intelligibility in children with motor speech disorders: A phase one study.
Langlois C; Tucker BV; Sawatzky AN; Reed A; Boliek CA
J Commun Disord; 2020; 86():106003. PubMed ID: 32505858
[TBL] [Abstract][Full Text] [Related]
29. Intensive treatment of dysarthria secondary to stroke.
Mahler LA; Ramig LO
Clin Linguist Phon; 2012 Aug; 26(8):681-94. PubMed ID: 22774928
[TBL] [Abstract][Full Text] [Related]
30. [Dysarthria across Parkinson's disease progression. Natural history of its components: dysphonia, dysprosody and dysarthria].
Pinto S; Ghio A; Teston B; Viallet F
Rev Neurol (Paris); 2010 Oct; 166(10):800-10. PubMed ID: 20800250
[TBL] [Abstract][Full Text] [Related]
31. Speech motor stability in IPD: effects of rate and loudness manipulations.
Kleinow J; Smith A; Ramig LO
J Speech Lang Hear Res; 2001 Oct; 44(5):1041-51. PubMed ID: 11708525
[TBL] [Abstract][Full Text] [Related]
32. Spectral/Cepstral Analyses of Phonation in Parkinson's Disease before and after Voice Treatment: A Preliminary Study.
Alharbi GG; Cannito MP; Buder EH; Awan SN
Folia Phoniatr Logop; 2019; 71(5-6):275-285. PubMed ID: 31117110
[TBL] [Abstract][Full Text] [Related]
33. Speech Prosody Across Stimulus Types for Individuals with Parkinson's Disease.
K-Y Ma J; Schneider CB; Hoffmann R; Storch A
J Parkinsons Dis; 2015; 5(2):291-9. PubMed ID: 25697957
[TBL] [Abstract][Full Text] [Related]
34. Speech, Voice, and Communication.
Johnson JA
Int Rev Neurobiol; 2017; 134():1189-1205. PubMed ID: 28805569
[TBL] [Abstract][Full Text] [Related]
35. Effectiveness of Lee Silverman Voice Treatment (LSVT) on hypernasality in non-progressive dysarthria: the need for further research.
Wenke RJ; Theodoros D; Cornwell P
Int J Lang Commun Disord; 2010; 45(1):31-46. PubMed ID: 19565392
[TBL] [Abstract][Full Text] [Related]
36. An Efficacy Study of Voice Quality Using Cepstral Analyses of Phonation in Parkinson's Disease before and after SPEAK-OUT!®.
Boutsen FR; Park E; Dvorak JD
Folia Phoniatr Logop; 2023; 75(1):35-42. PubMed ID: 35817007
[TBL] [Abstract][Full Text] [Related]
37. Articulatory network reorganization in Parkinson's disease as assessed by multimodal MRI and acoustic measures.
Klobusiakova P; Mekyska J; Brabenec L; Galaz Z; Zvoncak V; Mucha J; Rapcsak SZ; Rektorova I
Parkinsonism Relat Disord; 2021 Mar; 84():122-128. PubMed ID: 33609963
[TBL] [Abstract][Full Text] [Related]
38. Using Crowdsourced Listeners' Ratings to Measure Speech Changes in Hypokinetic Dysarthria: A Proof-of-Concept Study.
Nightingale C; Swartz M; Ramig LO; McAllister T
Am J Speech Lang Pathol; 2020 May; 29(2):873-882. PubMed ID: 32331503
[TBL] [Abstract][Full Text] [Related]
39. Treatments for dysarthria in Parkinson's disease.
Pinto S; Ozsancak C; Tripoliti E; Thobois S; Limousin-Dowsey P; Auzou P
Lancet Neurol; 2004 Sep; 3(9):547-56. PubMed ID: 15324723
[TBL] [Abstract][Full Text] [Related]
40. Single Word Intelligibility of Individuals with Parkinson's Disease in Noise: Pre-Specified Secondary Outcome Variables from a Randomized Control Trial (RCT) Comparing Two Intensive Speech Treatments (LSVT LOUD vs. LSVT ARTIC).
Schulz G; Halpern A; Spielman J; Ramig L; Panzer I; Sharpley A; Freeman K
Brain Sci; 2021 Jun; 11(7):. PubMed ID: 34199093
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
